ArticleBMC cancer2026
Antiviral therapy and hidden predictors of postoperative outcomes in hepatocellular carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a global health burden and hepatitis B virus (HBV) infection is a common cause. Antiviral therapy has the possibility to reduce the incidence of HCC, and recurrence of HCC after surgical resection.
methodsA total of 410 HCC patients had hepatectomy at Zhongnan hospital of Wuhan University. Categorization of these patients was done on the basis of HBV antiviral therapy. Recurrence-free survival (RFS) and the overall survival (OS) rates were assessed during follow-up period. Tumor necrosis percentage, recovery of liver functions, and tumor-related characteristics were also examined in these patients. Statistical analyses were conducted using Kaplan-Meier survival curves and Cox regression models.
resultsAfter applying strict selection criteria, only 93 patients formed the observation group. These patients had comparatively smaller tumor size ≤5 cm(76.3% vs. 45.1%) and less tumor necrosis (30.1% vs. 54.6%). OS (p = 0.035) and RFS (p = 0.034) was also improved in the observation group. However, antiviral therapy did not show any significant effect on OS (p = 0.188) and RFS (p = 0.527) after a multivariate adjustment. Microvascular invasion of more than 5 foci (OS HR = 2.96; RFS HR = 1.97), poor differentiation (RFS HR = 2.70), and stage C versus 0 of BCLC (OS HR = 3.75; RFS HR = 4.40) were independent adverse prognostic factors. Kaplan-Meier analysis indicated that tumour necrosis was associated with overall survival (OS) and recurrence-free survival (RFS), and this finding was validated in sensitivity analyses.
conclusionWhile antiviral therapy correlated with improved tumor pathology and univariate survival outcomes, it was not an independent prognostic factor after adjustment. Tumor necrosis independently predicted worse OS and RFS. Prognosis was primarily driven by microvascular invasion, poor differentiation, and advanced BCLC stage, suggesting antiviral benefits may operate indirectly through tumor biology modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.